Metaplastic Breast Carcinoma: Case Series and Review of the Literature

Eşbah, Onur; Türköz, Fatma Paksoy; Türker, İbrahim; Durnalı, Ayşe; Ekinci, Ahmet; Bal, Öznur; Sönmez, Özlem; Budakoğlu, Burçin; Arslan, Ulku Yalcintas; Öksüzoğlu, Berna

doi:10.7314/apjcp.2012.13.9.4645

Cited by 57 publications

(70 citation statements)

References 31 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Esbah et al (2) revealed that the poor prognosis of metaplastic carcinoma may be explained by the increased tumor size, higher proliferation index, histopathological tumor heterogeneity, triple negative feature and lack of effective targeted therapies. Previous studies (4,10,11) demonstrate that a more regular and more circumscribed mass may reflect a higher histological grade, while those lesions that appear benign may reflect tumor aggressiveness associated with a poorer prognosis and a low survival rate.…”

Section: Pathological Type Of Carcinoma Sonography ------------------mentioning

confidence: 99%

“…It typically presents as triple negative, therefore the effects of hormonotherapy are limited (3,4). Due to the heterogeneity of metaplastic carcinoma and its increased complexity compared with more common types of breast cancer, mixed chemotherapy regimens and dose schedules may be more effective and appropriate (2). Due to the distinction in surgical treatment and chemotherapy between metaplastic carcinoma and other breast cancers, it is particularly important to diagnose the tumor correctly (2).…”

Section: Introductionmentioning

confidence: 99%

“…Metaplastic carcinoma exhibits the metaplastic transformation of glandular epithelium to squamous epithelium and mesenchymal tissue, and accounts for <5% of all breast cancers (2) and may contain glandular and non-glandular components with mixed epithelial and mesenchymal tissue. Involvement of the axillary lymph node is rare, with hematogenous metastasis occurring more commonly in cases of metaplastic carcinoma (1,3).…”

Section: Introductionmentioning

confidence: 99%

“…Due to the heterogeneity of metaplastic carcinoma and its increased complexity compared with more common types of breast cancer, mixed chemotherapy regimens and dose schedules may be more effective and appropriate (2). Due to the distinction in surgical treatment and chemotherapy between metaplastic carcinoma and other breast cancers, it is particularly important to diagnose the tumor correctly (2). Metaplastic carcinoma demonstrates a number of benign features similar to invasive ductal carcinoma in mammograms and sonograms, and subsequently may be misdiagnosed as benign lesions (4).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Metaplastic carcinoma of the breast: Imaging and pathological features

Bian

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Metaplastic carcinoma of the breast is a rare form of breast cancer. The aim of the present study was to investigate the imaging and pathological features of metaplastic carcinoma. The features identified on mammography and sonography were retrospectively reviewed in 13 women with metaplastic carcinoma of the breast. The results from the mammographs and sonographs were additionally evaluated using immunohistochemical staining for the expression of the estrogen receptor (ER) and progesterone receptor (PR), receptor tyrosine-protein kinase erbB-2 (CerbB-2) and P53. The most common features observed in the mammographs were as follows: Irregular and oval shaped masses, 53.8 and 46.2%, respectively; spiculated and circumscribed margins, each 30.8%; and high and marginally high density masses, 69.2 and 30.8%, respectively. The most common sonography features observed were as follows: Hypoechoic masses, 84.6%; complex echogenicity, 76.9%; irregular, round and oval shaped masses, 69.2, 30.8 and 30.8%, respectively; indistinct and circumscribed margins, 53.8 and 46.2%, respectively; an abundant blood flow, 53.8%; and posterior acoustic enhancement, 61.5%. The immunohistochemical (IHC) profile for 13 patients demonstrated that ER was not expressed in 100% of patients, PR and CerbB-2 were not present in 92.3% of patients, and P53 was present in 63.6% of patients. Therefore, metaplastic carcinoma of the breast exhibits more benign IHC features compared with invasive ductal carcinoma. In addition, it may be challenging to diagnose patients that do not possess posterior acoustic enhancement or express hormone receptors from other types of breast cancer. IntroductionMetaplastic carcinoma of the breast is a rare form of breast cancer and possesses a poorer prognosis than other common types of breast cancer (1). Metaplastic carcinoma exhibits the metaplastic transformation of glandular epithelium to squamous epithelium and mesenchymal tissue, and accounts for <5% of all breast cancers (2) and may contain glandular and non-glandular components with mixed epithelial and mesenchymal tissue. Involvement of the axillary lymph node is rare, with hematogenous metastasis occurring more commonly in cases of metaplastic carcinoma (1,3). Metaplastic carcinoma demonstrates a poorer prognosis and a higher risk of recurrence compared with other types of breast cancer (3). It typically presents as triple negative, therefore the effects of hormonotherapy are limited (3,4). Due to the heterogeneity of metaplastic carcinoma and its increased complexity compared with more common types of breast cancer, mixed chemotherapy regimens and dose schedules may be more effective and appropriate (2). Due to the distinction in surgical treatment and chemotherapy between metaplastic carcinoma and other breast cancers, it is particularly important to diagnose the tumor correctly (2). Metaplastic carcinoma demonstrates a number of benign features similar to invasive ductal carcinoma in mammograms and sonograms, and subsequently may be misdiagnosed as ...

show abstract

Section: Pathological Type Of Carcinoma Sonography ------------------mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Metaplastic carcinoma of the breast: Imaging and pathological features

Bian

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Additionally, adenosquamous carcinoma of the breast is a rare tumor that exists as one of the subgroups of metaplastic breast carcinoma (5). Metaplastic carcinoma occurs at a prevalence of 1% of all breast carcinomas (6). In the present study, a case is reported of adenosquamous carcinoma of the breast [invasive ductal carcinoma and squamous cell carcinoma (SCC)] following AML, with metastatic cutaneous lesions of invasive ductal carcinoma on the thorax and abdomen.…”

Section: Introductionmentioning

confidence: 94%

Atypical breast adenosquamous carcinoma following acute myeloid leukemia in a middle-aged woman: A case report

Hashemi

Shan²,

Jahantigh

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Adenosquamous carcinoma of the breast is a rare cancer that develops as glands and tubules admixed with solid nests of squamous cells in a spindle cell background. Furthermore, its occurrence following AML is also rare. To the best of our knowledge, based on a review of the relevant literature, thus far there have not been any welldocumented cases. In the present case report, we report on a middle-aged woman with a 2year history of acute myeloid leukemia (AML) who was admitted to hospital due to a mass in the right breast, with concurrent cutaneous lesions on the breast. The clinical and pathological investigations resulted in the diagnosis of adenosquamous carcinoma of the breast. The patient underwent a modified radical mastectomy (MRM). Subsequently, the patient received chemotherapy, involved-field radiation therapy and target therapy. At 9 months after the final cycle of chemotherapy, and while she was on targeted therapy with trastuzumab (6 mg administered every 3 weeks), the patient presented with extensive dermatomal skin lesions. A biopsy report revealed metastatic lesions of invasive ductal carcinoma in the abdomen, so chemotherapy resumed with a course lasting for 6 cycles, with the identical treatments, but lacking trastuzumab.

show abstract